| INTRODUC TI ON
Several novel therapeutic avenues are being explored with the aim of improving management strategies for people with haemophilia, including gene therapy approaches, RNA interference, factor VIII (FVIII) mimetics and blockade of tissue factor pathway inhibitor (TFPI). Although primary prophylaxis is considered optimal for people with severe haemophilia, 1 significant barriers to the efficient implementation of prophylaxis persist. These barriers include the development of inhibitors, which are neutralizing antibodies formed against allogeneic factor VIII (FVIII) or factor IX (FIX), resulting in the reduction or elimination of FVIII/FIX activity and ultimately leading to a suboptimal response to treatment, increased disease burden and morbidity, and reduced quality of life. [2] [3] [4] A further barrier is the need for intravenous (iv) injections, which are painful, time-consuming and require venous access that can be difficult to achieve, particularly in young children. 5, 6 Concizumab is among the novel therapeutics in clinical devel- the presence of inhibitors. [7] [8] [9] [10] Concizumab is therefore being developed for the prevention of bleeding episodes, including long-term prophylaxis, in patients with haemophilia A and B with or without inhibitors. As it is a mAb, concizumab allows subcutaneous (sc) administration, and as it exhibits good solubility and stability, it can be formulated as a liquid for use in a ready-and easy-to-use portable pen device.
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In EXPLORER1 (ClinicalTrials.gov identifier: NCT01228669), a first-in-human trial, concizumab exhibited a favourable safety profile following a single sc or iv dose administered to healthy volunteers or patients with haemophilia A or B. There were no serious adverse events and no anti-concizumab antibodies were reported.
In addition, a dose-dependent, pro-coagulant effect was observed, as well as a non-linear pharmacokinetic (PK) profile as a result of target-mediated clearance. 12 EXPLORER3 (NCT02490787) was a phase 1b, double-blind, multiple-dose escalation trial of sc concizumab in patients with severe haemophilia A without inhibitors.
In the primary analysis of EXPLORER3, no serious adverse events were seen in the completed cohorts, and a PK/pharmacodynamic (PD) relationship for concizumab dose, free TFPI and thrombin generation was confirmed. 13 Currently, concizumab is being assessed in phase 2 clinical trials in patients with severe haemophilia A without inhibitors (EXPLORER5; NCT03196297), as well as in patients with haemophilia A or B with inhibitors (EXPLORER4; NCT03196284).
Here, we present results from exploratory PK/PD analyses of data from concizumab phase 1/1b trials, which aimed to determine the association between concizumab exposure and the PD markers free TFPI and peak thrombin generation. Although the EXPLORER3 trial was not sufficiently powered to establish a prophylactic effect in terms of bleeding, the reported bleeding episodes from the trial were also included in the analyses. Through these analyses, we aimed to confirm the mechanism of action of concizumab by showing a decrease in free TFPI, expected to be accompanied by an increase in coagulation (seen as an increase in thrombin generation potential), and ultimately reflected clinically as a reduction in the number of bleeding episodes. The PK/PD analyses presented herein guided the design of the concizumab phase 2 studies, specifically in terms of dose setting. kg) were planned, but the trial was finalized after completion of the 0.8 mg/kg cohort based on coagulation and PK parameter changes that were observed in the 0.8 mg/kg cohort, as well as the high interpatient variation in the PK parameters and pro-coagulant response to concizumab in this cohort. No serious adverse events were observed in the completed dose groups. 13 Each patient in EXPLORER3 received the first two doses on two consecutive days to allow steady state to be reached rapidly, followed by subsequent administration once every 4 days.
| MATERIAL S AND ME THODS
All concizumab trials were conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice guidelines.
The trials were approved by the relevant ethics committees or institutional review boards. Written signed informed consent was obtained from all participants.
| Concizumab population PK model
A PK model was constructed based on all available iv and sc clinical data for concizumab doses >0.05 mg/kg and up to 9 mg/kg (data from 42 patients and 13 healthy volunteers). were comparable to those reported for other mAbs. 14 As the maximum elimination rate of the Michaelis Menten component (V max ) related to target-mediated clearance is high, the total clearance for low concentrations was estimated to be ~100-fold higher than at full saturation of the target. Variability simulations were performed by using individually estimated parameters, and by repeating interoccasion variability components as estimated within patients. A detailed description of the PK model is provided in a separate manuscript (in preparation).
| Concizumab PK/PD modelling

| Concizumab exposure-free TFPI E max model
An estimated exposure-response (E max ) model, based on all concizumab phase 1/1b data for which simultaneously collected concizumab and free TFPI samples were available, was constructed to determine the relationship between concizumab concentration and the affinity to its target (ie, TFPI) ( Figure 1) . A basic assumption in this approach is that the effect of concizumab on free TFPI concentration is in steady state and is based on the half-life of concizumab being much larger than the half-life of TFPI. 12, 15 All pre-dose samples from EXPLORER1 patients treated with concizumab iv were excluded from the analysis as some of them had been spiked with concizumab prior to the analysis. Sigmoidal E max models with between-subject variability on baseline and half-maximal effective concentration (EC 50 ) and covariates on baseline and EC 50 were investigated. Both statistical tests and visual inspection of goodnessof-fit were used for decisions on model structure. Terms were only considered if they were judged to be pharmacologically meaningful.
Likelihood ratio tests at 5% significance level were used throughout.
The sigmoidal E max model of the free TFPI concentration predicted by the concizumab concentration was designed as an E max model of free TFPI reduction from baseline (at zero concizumab concentration). Full reduction resulted in a free TFPI concentration at the lower limit of quantification (LLOQ). TFPI LLOQ varied between trials (12.5 ng/mL for EXPLORER1 and the Japanese trial, and 17.0 and 9.6 ng/mL for EXPLORER2 and EXPLORER3, respectively). The model was developed in a stepwise fashion. 
| Concizumab exposure-thrombin generation potential association
Analyses of peak thrombin generation vs concizumab concentrations were constructed based on observations in the EXPLORER3 trial (data from 24 patients).
A sigmoidal E max model of the logarithm of peak thrombin generation was fitted with concizumab concentration as explanatory variable. (Table 1) . Subject-level random effects were significant on both baseline free TFPI concentration and EC 50 . The trial effect leading to the smallest P-value was obtained by grouping EXPLORER1 with the Japanese trial data and the EXPLORER2 with EXPLORER3 data. It was observed that the random effect on EC 50 led to very large EC 50 values for two of the three patients receiving 9 mg/kg iv. As 9 mg/kg is considerably higher than the concizumab doses administered to patients in clinical trials, it was decided to test the effect of this dose level on EC 50
in order for these observations not to have too large an influence on the EC 50 estimate for a typical subject. The estimated typical value for EC 50 was 62 ng/mL. The combined trial effect of EXPLORER1 and the Japanese study was significant on model-predicted baseline TFPI concentration, while data for concizumab 9 mg/kg iv had a significant effect on EC 50 .
In data described by the E max model, a tight PK/PD relationship was observed between concizumab exposure and free TFPI, with free TFPI decreasing with increasing concizumab concentration ( Figure 2) . A similar TFPI baseline distribution (at zero concizumab concentration) was predicted for patients receiving placebo and for pre-dose samples. 
F I G U R E 2
Relationship between concizumab exposure, free tissue factor pathway inhibitor (TFPI) and bleeding episodes. Estimated exposure-response (E max ) model of free TFPI predictions based on all concizumab phase 1/1b data for which simultaneously collected concizumab and free TFPI samples were available are shown. Free TFPI predictions relative to the predicted baseline free TFPI concentration vs observed concizumab concentration are shown. At bleeding events in EXPLORER3 (red dots), concizumab concentration was predicted using a population pharmacokinetic model (based on all available intravenous and subcutaneous clinical data for concizumab doses >0.05 mg/kg and up to 9 mg/kg) and, subsequently, free TFPI concentration was predicted using a concizumab−free TFPI E max model. The solid line represents predictions of free TFPI concentration vs concizumab concentration for a typical subject. A typical subject was defined as a subject from EXPLORER2 or EXPLORER3 with typical baseline TFPI concentration and EC 50 value. Jitter has been added to free TFPI levels for bleeds at predicted PK levels below 10 ng/mL in order to distinguish points graphically. The same has been done to observations at full reduction of free TFPI. Predictions are not shown for concizumab 9 mg/kg
| Concizumab exposure-thrombin generation potential association
A sigmoidal E max relationship was identified between concizumab plasma concentration and peak thrombin generation potential in EXPLORER3 ( Figure 3) . A number of observations of peak thrombin generation within the normal range were noted at low concizumab levels, potentially representing the effect of residual FVIII, which, in theory, could be either through secondary missense mutations or due to the long terminal half-life of administered FVIII. Since these observations constitute a considerable part of the residual variability, more detailed effects, such as random effects, were not investigated. The estimated typical EC 50 value (ie, the concizumab concentration predicted to give 50% of the maximum possible effect on peak thrombin generation) was 63 ng/mL.
There was a strong correlation between concizumab concentration and peak thrombin generation potential in data collected in EXPLORER3, with concizumab >100 ng/mL re-establishing throm- ≤20, >20 to ≤100 and >100 ng/mL, respectively.
| Concizumab exposure-bleeding episode association
As EXPLORER3 was not an efficacy trial, a prophylactic effect of concizumab administration in terms of bleeding events could not be assessed. However, a correlation between the frequency of bleeding episodes and concizumab concentration was indicated, with fewer bleeds observed at concizumab concentrations >100 ng/ mL and at free TFPI levels <25% relative to baseline (Figure 2 ). It should be noted that there was substantially less exposure time with concizumab concentrations above 100 ng/mL vs those below 100 ng/mL.
| D ISCUSS I ON
In PK/PD analyses of EXPLORER3 data, it was noted that at concizumab exposure levels >100 ng/mL, the thrombin generation potential was re-established to predominantly within the normal range. Additionally, results from PK/PD analyses of concizumab phase 1/1b data indicated a clinically relevant prophylactic effect for haemophilia patients at concizumab exposure levels >100 ng/ mL, based on the decrease in reported bleeding episodes noted at estimated concizumab exposure above that level. The PK/PD results obtained were consistent across all concizumab phase 1/1b trials.
Based on these results, the concizumab phase 2 clinical development programme has been designed to target a concizumab exposure of at least 100 ng/mL. In addition, a once-daily, efficacy-based, individual, dose-escalation regimen has been selected for the phase 2 trials with the aim of reducing PK variability (previously noted in the highest dose cohort in EXPLORER3, receiving 0.8 mg/kg, once every 4 days). 16 The results from the current PK/PD analyses should be considered in the light of the fact that patients had not been randomized to concizumab exposure/dose, which represents a limitation when conducting exposure-response analyses.
In EXPLORER4, patients with haemophilia A or B with inhibitors will receive a loading dose of concizumab 0.5 mg/kg as the first dose, followed by 0.15 mg/kg (sc, daily), with potential They will also provide a larger data set and results based on a longer exposure to concizumab, thus expanding the scope of the current analyses.
Our analyses showed a strong correlation between concizumab exposure and free TFPI. The estimated typical EC 50 values for concizumab-free TFPI and concizumab-thrombin generation were very similar (62 and 63 ng/mL, respectively), a result that supports free TFPI (ie, TFPI in plasma, not bound to concizumab) as a useful biomarker for concizumab efficacy. Moreover, there was an indication of fewer bleeds at lower free TFPI concentrations.
There are several advantages associated with the use of concizumab for the treatment of patients with haemophilia. As previously noted, its unique mechanism of action renders it applicable for both haemophilia A and B patients, both with or without inhibitors. As a sc therapeutic, treatment with concizumab should result in a significant improvement in compliance in terms of prophylaxis and therefore lead to improved treatment outcomes, including in patients with severe haemophilia, in whom prophylactic treatment is recommended and can help maintain normal musculoskeletal function. 1 An additional advantage associated with concizumab is its availability as a liquid formulation with a long shelf-life that can be easily administered at small volumes via a portable pen device stored at room temperature. In a small pen injector handling test among haemophilia patients accustomed to using syringe-to-vial systems, a positive response to the pen device was noted, with no handling difficulties or errors documented. 11 Crucially, as concizumab is a mAb, there is no risk of developing inhibitors towards coagulation factors, the most significant complication associated with factor replacement treatment. [2] [3] [4] Finally, and of note, no neutralizing anti-drug antibodies were observed following treatment with concizumab in any of the phase 1/1b trials.
| CON CLUS ION
Based on the results of the PK/PD analyses presented herein, the phase 2 concizumab clinical development programme has been designed to target an exposure of at least 100 ng/mL, and a once-daily, efficacy-based, individual dose-escalation regimen has been selected to reduce exposure variability. The minimum concizumab exposure level required to achieve sufficient haemostatic efficacy will be fine-tuned following the availability of phase 2 clinical data.
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